TISSUE PLASMINOGEN-ACTIVATOR TREATMENT OF EXPERIMENTAL SUBRETINAL HEMORRHAGE

被引:52
作者
JOHNSON, MW
OLSEN, KR
HERNANDEZ, E
机构
[1] Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami School of Medicine, Miami, FL
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 1991年 / 11卷 / 02期
关键词
Fibrinolysis; Macular degeneration; Sub-retinal hemorrhage; Thrombolysis; Tissue plasminogen activator; Vitreoretinal surgery;
D O I
10.1097/00006982-199111020-00011
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Previous investigators have suggested that subretinal blood damages the retina in part because of its solid fibrin meshwork. The role of fibrinolysis in facilitating the clearance of subretinal hemorrhage and preventing degeneration of the overlying retina was studied. Autologous whole blood (0.1 ml) was injected into the subretinal space of 20 rabbits. Twenty-four hours later, the animals were randomized to subretinal treatment with 2.5-mu-g of tissue plasminogen activator or a similar volume of physiologic saline. Mean subretinal hemorrhage thickness 3 days after treatment had decreased to 42% of pretreatment thickness in treated eyes and remained unchanged in control eyes (P < 0.0005). By 7 days mean clot thickness was 9% in treated eyes and 60% in controls (P = 0.005). Light microscopy revealed severe progressive retinal degeneration in both groups. No histologic evidence of retinal toxicity was found in cat retina after subretinal injection of tissue plasminogen activator (50-mu-g/ml). Although treatment with tissue plasminogen activator accelerated the clearance of subretinal hemorrhage, it failed to prevent secondary retinal degeneration in this rabbit model.
引用
收藏
页码:250 / 258
页数:9
相关论文
共 44 条
[31]  
Regnault F.R., Vitreous hemorrhage: An experimental study. III. Experimental degeneration of the rabbit retina induced by hemoglobin injection into the vitreous, Arch Ophthalmol, 83, pp. 470-474, (1970)
[32]  
Cibis P.A., Yamashita T., Experimental aspects of ocular siderosis and hemosiderosis, Am J Ophthalmol, 48, pp. 465-480, (1959)
[33]  
Johnson M.W., Olsen K.R., Hernandez, Et al., Retinal toxicity of recombinant tissue plasminogen activator in the rabbit, Arch Ophthalmol, 108, pp. 259-263
[34]  
Morse L.S., Toth C.A., Hjelmeland L.M., Landers M.B., Tissue plasminogen activator beneath the retina of the cat, Invest Oph Thalmol Vis Sci, 31, (1990)
[35]  
Gass J.D.M., Pathogenesis of disciform detachment of the neuroep-ithelium. III. Senile disciform macular degeneration, Am J Ophthalmol, 63, pp. 617-644, (1967)
[36]  
Verhoeff F.H., Grossman H.P., Pathogenesis of disciform degeneration of the macula, Arch Ophthalmol, 18, pp. 561-585, (1937)
[37]  
Garner A., Pathology of macular degeneration in the elderly, Trans Ophthalmol Soc UK, 95, pp. 54-61, (1975)
[38]  
Vidaurri-Leal J.S., Glaser B.M., Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells, Arch Ophthalmol, 102, pp. 1376-1379, (1984)
[39]  
Rogers S.D., Riemersma L.B., Clements S.D., Tissue plasminogen activator: An evaluation of clinical efficacy in acute myocardial infarction, Pharmacotherapy, 7, pp. 111-121, (1987)
[40]  
Ozment R.R., Liaw Z.C., Krug J., Et al., Use of tissue plasminogen activator in experimental filtration surgery, Invest Ophthalmol Vis Sci, 30, (1989)